Newly defined problems with CGRP monoclonal inhibitor drugs for Migraine prevention.

Certain problems were not adequately addressed when the CGRP drugs Aimovig, Ajovy, Emgality, Vyepti, Nurtec, and Qulipta first came out. Longer analysis has revealed new safety issues not found in the initial clinical trials.

This is an article by Britt Talley Daniel MD, retired member of the American Academy of Neurology, Migraine textbook author, Podcaster, YouTube video producer, and Blogger.

List of the recently indicated problems:

Significant elevation of blood pressure (hypertension).

Severe constipation

Potential cardiovascular risks in patients with pre-existing vascular issues.

Elevated blood pressure (Hypertension)

This was originally not thought to be a problem, but it may be found that these drugs cause a rise of several points in blood pressure. These patients need long term home blood pressure monitoring and follow up with their doctor. Erenumab (Aimovig) has particularly come under suspicion.

Severe constipation

Few of the sufferings of life may be as great as constipation and a chronic, severe case is very disarming. Who could live with such a problem?

Potential cardiovascular risks in patients with pre-existing vascular issues.

Angina, Myocardial infarction, TIA, Stroke, arrhythmia-these are medical problems that always need prompt attention and shouldn’t be ignored.

It is a pharmacological backstep that CGRP drugs for some patients present with such problems because they work so well for migraine prevention.

CGRP drugs are not recommended for pregnancy.

This site is owned and operated by Internet School LLC, a limited liability company headquartered in Dallas, Texas, USA.

Although this site provides information about various medical conditions, the reader is directed to his own treating physician for medical treatment.

Follow me at:  www.doctormigraine.com, Pinterest, Amazon books, Podcasts with Spreaker, and YouTube.

All the best.

Britt Talley Daniel MD